Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−38.09 M CAD
0.00 CAD
28.57 M
About EUPRAXIA PHARMACEUTICALS INC
Sector
Industry
CEO
James A. Helliwell
Website
Headquarters
Victoria
Founded
2011
FIGI
BBG00Z83VR67
Eupraxia Pharmaceuticals, Inc. operates as a drug delivery technology company in Canada. It delivers drugs into body compartments, such as the joint without any of the common issues with body compartment injections, such as systemic exposure. The firm focuses on arthritis, diabetic macular edema, and chronic pain programs. The company was founded by James A. Helliwell and John Salvatore Montalbano on May 12, 2011 and is headquartered in Victoria, Canada.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of EPRX is 4.49 CAD — it has increased by 2.05% in the past 24 hours. Watch EUPRAXIA PHARMACEUTICALS INC stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on TSX exchange EUPRAXIA PHARMACEUTICALS INC stocks are traded under the ticker EPRX.
EPRX stock has fallen by −5.47% compared to the previous week, the month change is a −5.07% fall, over the last year EUPRAXIA PHARMACEUTICALS INC has showed a −18.51% decrease.
We've gathered analysts' opinions on EUPRAXIA PHARMACEUTICALS INC future price: according to them, EPRX price has a max estimate of 16.73 CAD and a min estimate of 8.25 CAD. Watch EPRX chart and read a more detailed EUPRAXIA PHARMACEUTICALS INC stock forecast: see what analysts think of EUPRAXIA PHARMACEUTICALS INC and suggest that you do with its stocks.
EPRX reached its all-time high on Jul 5, 2023 with the price of 9.10 CAD, and its all-time low was 0.80 CAD and was reached on May 10, 2022. View more price dynamics on EPRX chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
EPRX stock is 2.05% volatile and has beta coefficient of 0.22. Track EUPRAXIA PHARMACEUTICALS INC stock price on the chart and check out the list of the most volatile stocks — is EUPRAXIA PHARMACEUTICALS INC there?
Today EUPRAXIA PHARMACEUTICALS INC has the market capitalization of 159.94 M, it has decreased by −6.38% over the last week.
Yes, you can track EUPRAXIA PHARMACEUTICALS INC financials in yearly and quarterly reports right on TradingView.
EUPRAXIA PHARMACEUTICALS INC is going to release the next earnings report on Apr 1, 2025. Keep track of upcoming events with our Earnings Calendar.
EPRX earnings for the last quarter are −0.17 CAD per share, whereas the estimation was −0.18 CAD resulting in a 4.77% surprise. The estimated earnings for the next quarter are −0.20 CAD per share. See more details about EUPRAXIA PHARMACEUTICALS INC earnings.
EUPRAXIA PHARMACEUTICALS INC revenue for the last quarter amounts to 0.00 CAD, matching the estimated figure, and no changes in revenue are expected for the next quarter.
EPRX net income for the last quarter is −8.11 M CAD, while the quarter before that showed −8.22 M CAD of net income which accounts for 1.37% change. Track more EUPRAXIA PHARMACEUTICALS INC financial stats to get the full picture.
No, EPRX doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, EPRX shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade EUPRAXIA PHARMACEUTICALS INC stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So EUPRAXIA PHARMACEUTICALS INC technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating EUPRAXIA PHARMACEUTICALS INC stock shows the neutral signal. See more of EUPRAXIA PHARMACEUTICALS INC technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.